| Literature DB >> 28144504 |
Oihane K Arriortua1, Eneko Garaio1, Borja Herrero de la Parte2, Maite Insausti3, Luis Lezama3, Fernando Plazaola1, Jose Angel García3, Jesús M Aizpurua4, Maialen Sagartzazu4, Mireia Irazola1, Nestor Etxebarria1, Ignacio García-Alonso2, Alberto Saiz-López5, José Javier Echevarria-Uraga5.
Abstract
This work reports important advances in the study of magnetic nanoparticles (MNPs) related to their application in different research fields such as magnetic hyperthermia. Nanotherapy based on targeted nanoparticles could become an attractive alternative to conventional oncologic treatments as it allows a local heating in tumoral surroundings without damage to healthy tissue. RGD-peptide-conjugated MNPs have been designed to specifically target αVβ3 receptor-expressing cancer cells, being bound the RGD peptides by "click chemistry" due to its selectivity and applicability. The thermal decomposition of iron metallo-organic precursors yield homogeneous Fe3O4 nanoparticles that have been properly functionalized with RGD peptides, and the preparation of magnetic fluids has been achieved. The nanoparticles were characterized by transmission electron microscopy (TEM), vibrating sample magnetometry (VSM), electron magnetic resonance (EMR) spectroscopy and magnetic hyperthermia. The nanoparticles present superparamagnetic behavior with very high magnetization values, which yield hyperthermia values above 500 W/g for magnetic fluids. These fluids have been administrated to rats, but instead of injecting MNP fluid directly into liver tumors, intravascular administration of MNPs in animals with induced colorectal tumors has been performed. Afterwards the animals were exposed to an alternating magnetic field in order to achieve hyperthermia. The evolution of an in vivo model has been described, resulting in a significant reduction in tumor viability.Entities:
Keywords: RGD functionalization; magnetic hyperthermia; magnetite nanoparticles; tumor targeting
Year: 2016 PMID: 28144504 PMCID: PMC5238624 DOI: 10.3762/bjnano.7.147
Source DB: PubMed Journal: Beilstein J Nanotechnol ISSN: 2190-4286 Impact factor: 3.649
Figure 1TEM images of a) Fe3O4@OA and b) Fe3O4@PMAO with the diameter size distribution shown between the images.
Figure 2a) Experimental M vs H hysteresis cycles at 300 and 5 K and b) Magnetization of the zero-field-cooled (ZFC) and field-cooled (FC) Fe3O4@OA sample.
Figure 3EMR spectrum at room temperature for the Fe3O4@OA sample measured in toluene.
Figure 4SAR values versus applied magnetic field intensity (Happ) at different field frequencies for the Fe3O4@PMAO_RGD water dispersed nanoparticles.
Results of the measurements in the two groups of rats. SG: Control group, eight rats infused with saline. MNpG: group of eight rats infused with MNPs. ∆Tª: temperature increase quantified at the end of the hyperthermia induction cycle. Tumour necrosis (%): percentage of tumor necrosis established by pathologic analysis. The values are expressed as the mean (±SD) when they are adjusted to a Gaussian distribution or median (range) otherwise.
| SG | MNpG | |||
| Weight (g) | 269 (±18.9) | 252 (±20.2) | 0.11 | |
| Tumor volume (mm3) | 0.41 (±0.22) | 0.46 (±0.19) | 0.42 | |
| ∆ | 4.66 (±0.99) | 7.89 (±1.2) | <0.05 | |
| ∆ | 2.45 (±0.82) | 2.39 (±1.4) | 0.73 | |
| ∆ | 4.73 (±0.98) | 7.76 (±0.63) 43 (39–43) | <0.05 | |
| ICP–MS [Fe] (µg·g−1) | ||||
| Tumor | 51 (±7.38) | 93 (±35.56) | <0.05 | |
| Tumor necrosis (%) | 4 (1–13) | 20 (3–99) | <0.05 | |
Figure 5Kupffer cells with phagocytized iron deposits (blue dots) in liver tissue. In the fibro-vascular tissue matrix around the tumor (asterisks) blue iron deposits are observed.
Figure 6Error bars show the percentages of tumor necrosis in rats infused with saline or magnetic nanoparticles. A significant difference can be observed between the two groups of rats (p = 0.01).
Figure 7Scheme of the AC magnetometer with the air-core coil and the oppositely wound pick-up coils.